Tags

Type your tag names separated by a space and hit enter

[Parvovirus B19 infection in patients with congenital blood coagulation disorders].
Med Clin (Barc). 1997 May 03; 108(17):641-6.MC

Abstract

BACKGROUND

The aim of this study is to assess the prevalence of Parvovirus B19 infection in a group of patients affected by congenital coagulation disorders and its association with epidemiological aspects.

PATIENTS AND METHODS

We have analyzed a group of 50 patients (median age 28) diagnosed with haemophilia or any other congenital coagulation disorder and 111 healthy non-transfused controls (median age 30) for IgG and IgM antibodies to Parvovirus B19 (Dako A/S, Glostrup, Dinamarca). Other issues analysed were HIV coinfection, the use of virally inactivated or non-inactivated plasma products and clinical symptoms of the infection.

RESULTS

84% of the patients (93.3% of those previously transfused) and 60.3% of the controls subjects showed IgG antibodies against Parvovirus B19. None of them had specific IgM antibodies. Five patients (all of them seronegative) had never been exposed to any plasma derivative and 11 were HIV-positive. The differences found between the prevalence of parvoviral infection in patients and controls are statistically significant, but those differences are only confirmed in younger patients (< 30) when age groups are compared. However, the severity of the haemostatic disorder, the type of plasma products infused or HIV coinfection had no influence on prevalence rates. The infection was clinically asymptomatic in all the cases.

CONCLUSIONS

Haemophilic patients of any age are exposed to a higher risk of Parvovirus B19 infection than general population, although this infection had no clinical relevance in our study. The use of virally inactivated factor concentrates or the severity of the haemostatic disorder has no influence on this infectious risk.

Authors+Show Affiliations

Servicio Regional de Hematología y Hemoterapia, Hospital Miguel Servet, Zaragoza.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

spa

PubMed ID

9312580

Citation

Aguilar Franco, C, et al. "[Parvovirus B19 Infection in Patients With Congenital Blood Coagulation Disorders]." Medicina Clinica, vol. 108, no. 17, 1997, pp. 641-6.
Aguilar Franco C, Lucía Cuesta JF, Ferrer Torres J, et al. [Parvovirus B19 infection in patients with congenital blood coagulation disorders]. Med Clin (Barc). 1997;108(17):641-6.
Aguilar Franco, C., Lucía Cuesta, J. F., Ferrer Torres, J., & Omeñaca Teres, M. (1997). [Parvovirus B19 infection in patients with congenital blood coagulation disorders]. Medicina Clinica, 108(17), 641-6.
Aguilar Franco C, et al. [Parvovirus B19 Infection in Patients With Congenital Blood Coagulation Disorders]. Med Clin (Barc). 1997 May 3;108(17):641-6. PubMed PMID: 9312580.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Parvovirus B19 infection in patients with congenital blood coagulation disorders]. AU - Aguilar Franco,C, AU - Lucía Cuesta,J F, AU - Ferrer Torres,J, AU - Omeñaca Teres,M, PY - 1997/5/3/pubmed PY - 1997/10/6/medline PY - 1997/5/3/entrez SP - 641 EP - 6 JF - Medicina clinica JO - Med Clin (Barc) VL - 108 IS - 17 N2 - BACKGROUND: The aim of this study is to assess the prevalence of Parvovirus B19 infection in a group of patients affected by congenital coagulation disorders and its association with epidemiological aspects. PATIENTS AND METHODS: We have analyzed a group of 50 patients (median age 28) diagnosed with haemophilia or any other congenital coagulation disorder and 111 healthy non-transfused controls (median age 30) for IgG and IgM antibodies to Parvovirus B19 (Dako A/S, Glostrup, Dinamarca). Other issues analysed were HIV coinfection, the use of virally inactivated or non-inactivated plasma products and clinical symptoms of the infection. RESULTS: 84% of the patients (93.3% of those previously transfused) and 60.3% of the controls subjects showed IgG antibodies against Parvovirus B19. None of them had specific IgM antibodies. Five patients (all of them seronegative) had never been exposed to any plasma derivative and 11 were HIV-positive. The differences found between the prevalence of parvoviral infection in patients and controls are statistically significant, but those differences are only confirmed in younger patients (< 30) when age groups are compared. However, the severity of the haemostatic disorder, the type of plasma products infused or HIV coinfection had no influence on prevalence rates. The infection was clinically asymptomatic in all the cases. CONCLUSIONS: Haemophilic patients of any age are exposed to a higher risk of Parvovirus B19 infection than general population, although this infection had no clinical relevance in our study. The use of virally inactivated factor concentrates or the severity of the haemostatic disorder has no influence on this infectious risk. SN - 0025-7753 UR - https://www.unboundmedicine.com/medline/citation/9312580/[Parvovirus_B19_infection_in_patients_with_congenital_blood_coagulation_disorders]_ L2 - https://medlineplus.gov/bleedingdisorders.html DB - PRIME DP - Unbound Medicine ER -